CD274 and melanoma: In recent years, immune checkpoint inhibitors, such as anti-PD-1, anti-PD-L1, and anti-CTLA-4 antibodies, have been demonstrated to release T cells from their exhausted state and restore cytotoxic functions, significantly improving therapeutic responses in a subset of melanoma patients (Wang K. et al., 2024).